NASDAQ:AYTU Aytu BioPharma (AYTU) Stock Price, News & Analysis $2.02 -0.01 (-0.49%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$2.04 +0.02 (+0.99%) As of 04:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Aytu BioPharma Stock (NASDAQ:AYTU) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aytu BioPharma alerts:Sign Up Key Stats Today's Range$2.00▼$2.0650-Day Range$1.00▼$2.5952-Week Range$0.95▼$3.24Volume376,594 shsAverage Volume318,012 shsMarket Capitalization$12.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Read More… Aytu BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreAYTU MarketRank™: Aytu BioPharma scored higher than 36% of companies evaluated by MarketBeat, and ranked 717th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Aytu BioPharma. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Aytu BioPharma is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aytu BioPharma is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAytu BioPharma has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.27% of the float of Aytu BioPharma has been sold short.Short Interest Ratio / Days to CoverAytu BioPharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aytu BioPharma has recently increased by 14.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAytu BioPharma does not currently pay a dividend.Dividend GrowthAytu BioPharma does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.45 Percentage of Shares Shorted2.27% of the float of Aytu BioPharma has been sold short.Short Interest Ratio / Days to CoverAytu BioPharma has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aytu BioPharma has recently increased by 14.41%, indicating that investor sentiment is decreasing significantly. News and Social Media3.9 / 5News Sentiment0.97 News SentimentAytu BioPharma has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aytu BioPharma this week, compared to 0 articles on an average week.Search Interest1 people have searched for AYTU on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Aytu BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Aytu BioPharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,500.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.60% of the stock of Aytu BioPharma is held by insiders.Percentage Held by InstitutionsOnly 33.49% of the stock of Aytu BioPharma is held by institutions.Read more about Aytu BioPharma's insider trading history. Receive AYTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AYTU Stock News HeadlinesAytu BioPharma Third Quarter 2025 Earnings: Beats ExpectationsMay 16, 2025 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing career. In a special event watched by thousands, he unveiled what he calls “the boldest undertaking” he’s ever attempted — a real-money initiative that will document every trade, decision, win, and loss in pursuit of a million-dollar mission. And the results are already surprising. One early beta tester tripled her investment income in just three trades.May 22, 2025 | Porter & Company (Ad)Aytu BioPharma Stock Price, Quotes and Forecasts | NASDAQ:AYTU | BenzingaMay 15, 2025 | benzinga.comAytu signals ongoing portfolio expansion opportunities as Q3 2025 revenue surges 32%May 15, 2025 | msn.comAytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comAytu BioPharma Q3 Earnings PreviewMay 14, 2025 | msn.comAytu BioPharma’s treatment of Marfan syndrome receives FDA orphan designationApril 15, 2025 | markets.businessinsider.comSee More Headlines AYTU Stock Analysis - Frequently Asked Questions How have AYTU shares performed this year? Aytu BioPharma's stock was trading at $1.70 at the beginning of 2025. Since then, AYTU shares have increased by 18.8% and is now trading at $2.02. View the best growth stocks for 2025 here. How were Aytu BioPharma's earnings last quarter? Aytu BioPharma, Inc. (NASDAQ:AYTU) posted its quarterly earnings data on Wednesday, May, 14th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.37. The company had revenue of $18.45 million for the quarter, compared to the consensus estimate of $13.74 million. Aytu BioPharma had a negative net margin of 7.62% and a negative trailing twelve-month return on equity of 19.30%. Read the conference call transcript. When did Aytu BioPharma's stock split? Aytu BioPharma's stock reverse split before market open on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Aytu BioPharma's major shareholders? Aytu BioPharma's top institutional shareholders include Stonepine Capital Management LLC (7.52%) and Armistice Capital LLC (0.93%). Insiders that own company stock include Joshua R Disbrow and Greg Pyszczymuka. View institutional ownership trends. How do I buy shares of Aytu BioPharma? Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aytu BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aytu BioPharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), GE Aerospace (GE), CymaBay Therapeutics (CBAY) and Adobe (ADBE). Company Calendar Last Earnings5/14/2025Today5/21/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AYTU CIK1385818 Webaytubio.com Phone(720) 437-6580FaxN/AEmployees160Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,840,000.00 Net Margins-7.62% Pretax Margin-8.90% Return on Equity-19.30% Return on Assets-4.80% Debt Debt-to-Equity Ratio0.32 Current Ratio0.98 Quick Ratio0.81 Sales & Book Value Annual Sales$77.23 million Price / Sales0.16 Cash FlowN/A Price / Cash FlowN/A Book Value$4.64 per share Price / Book0.44Miscellaneous Outstanding Shares6,170,000Free Float5,999,000Market Cap$12.46 million OptionableNot Optionable Beta-0.10 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:AYTU) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.